Sugi Predict

Sugi Predict / Compounds / SCHEMBL320185

SCHEMBL320185

SCHEMBL320185

OB(O)c1cc(Cl)ccc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.52
▸ TSHR P16473 2/20 0.52
▸ ERN1 O75460 1/20 0.48
▸ HPGD P15428 4/20 0.48
▸ ALOX15 P16050 4/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ ALOX12 P18054 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ CYP3A4 P08684 4/20 0.46
▸ HIF1A Q16665 4/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ HTT P42858 3/20 0.46
▸ HSP90AA1 P07900 2/20 0.46
▸ CYP2C9 P11712 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ SLC22A1 O15245 1/20 0.46
▸ USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31112067 1.00 HSD17B10 (0.52) HSD17B10TSHRERN1HPGDALOX15
SCHEMBL20625255 0.83 HSD17B10 (0.45) HSD17B10TSHRERN1HPGDALOX15
SCHEMBL2587772 0.81 HSD17B10 (0.52) HSD17B10TSHRERN1HPGDALOX15
SCHEMBL29954084 0.81 HSD17B10 (0.52) HSD17B10TSHRERN1HPGDALOX15
SCHEMBL29376152 0.78 TSHR (0.48) HSD17B10TSHRALOX15ALDH1A1SMN1; SMN2
SCHEMBL491658 0.78 TSHR (0.48) HSD17B10TSHRALOX15ALDH1A1SMN1; SMN2
SCHEMBL25365977 0.77 CYP2A6 (0.43) HSD17B10TSHRERN1HPGDALOX15
SCHEMBL25363704 0.77 CYP2A6 (0.43) HSD17B10TSHRERN1HPGDALOX15
SCHEMBL1349122 0.76 CYP3A4 (0.48) ALDH1A1CYP3A4MEN1KMT2AMAPT
SCHEMBL246398 0.76 ENPP2 (0.42) HSD17B10TSHRERN1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120118071-A Quinazoline compound and application thereof 北京化工大学 2025-06-10 — — CN claimed
CN-119751364-A Dimethoxy quinazoline compound and application thereof 中日友好医院(中日友好临床医学研究所) 2025-04-04 — — CN claimed
CN-118515534-B Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof 华南理工大学 2024-11-05 — — CN claimed
CN-118515534-A Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof 华南理工大学 2024-08-20 — — CN claimed
US-20250381187-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2025-12-18 — — US disclosed
US-20250359480-A1 ORGANIC LIGHT EMITTING DEVICE LG CHEMICAL LTD (KR) 2025-11-20 — — US disclosed
US-12440491-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2025-10-14 — — US disclosed
EP-4446327-B1 COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME LG CHEMICAL LTD (KR) 2025-09-24 — — EP disclosed
EP-4615441-A1 COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND USES THEREOF Ribometrix, Inc. (US) 2025-09-17 — — EP disclosed
EP-4615848-A1 COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND USES THEREOF Ribometrix, Inc. (US) 2025-09-17 — — EP disclosed
US-12415783-B2 Compound for organic electric element, organic electric element using same, and electronic apparatus thereof DUK SAN NEOLUX CO., LTD. (KR) 2025-09-16 — — US disclosed
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 ASTRAZENECA AB (SE) 2025-09-02 — — US disclosed
WO-2007125331-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-08 — — WO disclosed
WO-2007125331-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-08 — — WO disclosed
EP-1838304-A2 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2007-10-03 — — EP disclosed
US-20060264435-A1 Novel compounds ASTRAZENECA AB (SE) 2006-11-23 — — US disclosed
WO-2006065277-A2 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2006-06-22 — — WO disclosed
US-20060111370-A1 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION 2006-05-25 — — US disclosed
EP-1611091-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2006-01-04 — — EP disclosed
WO-2004089885-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 CX3CR1, CCR2, CCR5 HSD17B10 2866/4885TSHR 1113/4885ERN1 4426/4885
US-20060111370-A1 Heterocyclic aspartyl protease inhibitors CHRM1, CHRM2, PRSS1 HSD17B10 3077/4885TSHR 1151/4885ERN1 261/4885
US-20250381187-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS HSD17B10 3826/4885TSHR 4359/4885ERN1 1383/4885
US-12440491-B2 KRAS G12C inhibitors and methods of using the same KRAS, NRAS, HRAS HSD17B10 3826/4885TSHR 4359/4885ERN1 1383/4885
US-20060264435-A1 Novel compounds ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 HSD17B10 792/4885TSHR 2760/4885ERN1 4315/4885
US-12415783-B2 Compound for organic electric element, organic electric element using same, and electronic apparatus thereof OR51E2, SLC39A11, WEE1 HSD17B10 3367/4885TSHR 4555/4885ERN1 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.